Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Phase 2

Recruiting

Conditions: Hemophagocytic Lymphohistiocytoses

Interventions: Drug: Ruxolitinib
Drug: Etoposide
Drug: Dexamethasone
Procedure: Non-interventional Imaging
Procedure: Research Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2023-12-07

Last Posted Date: 2024-10-15

Lead Sponsor: Aaron Logan, MD

Target Recruit Count: 36

Registration Number: NCT06160791

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: ABBV-383
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Elotuzumab
Drug: Selinexor
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-12-06

Last Posted Date: 2024-11-04

Lead Sponsor: AbbVie

Target Recruit Count: 380

Registration Number: NCT06158841

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
🇺🇸
Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
🇺🇸
Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States

and more 80 locations

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Carfilzomib

First Posted Date: 2023-11-30

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 492

Registration Number: NCT06152575

Locations: 🇺🇸
Community Health Network, Inc., Indianapolis, Indiana, United States
🇺🇸
Cayuga Cancer Center at Cayuga Park, Ithaca, New York, United States
🇺🇸
Cayuga Medical Center, Ithaca, New York, United States

and more 109 locations

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Extramedullary Multiple Myeloma
Primary Plasma Cell Leukemia

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: epirubicin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: bortezomib

First Posted Date: 2023-11-21

Last Posted Date: 2024-01-03

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 54

Registration Number: NCT06140966

Locations: 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Phase 1

Active, not recruiting

Conditions: Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: Opevesostat
Drug: Dexamethasone
Drug: Fludrocortisone
Drug: Hydrocortisone

First Posted Date: 2023-11-18

Last Posted Date: 2024-11-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 14

Registration Number: NCT06136598

Locations: 🇨🇳
Peking University First Hospital-Urology ( Site 0001), Beijing, Beijing, China
🇨🇳
Tongji Hospital Tongji Medical,Science & Technology ( Site 0002), Wuhan, Hubei, China
🇨🇳
Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003), Guangzhou, Guangdong, China

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Phase 3

Recruiting

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Opevesostat
Drug: Abiraterone acetate
Drug: Hydrocortisone
Drug: Enzalutamide
Drug: Fludrocortisone acetate
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06136624

Locations: 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇳🇱
Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland, Netherlands
🇵🇱
Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie, Poland

and more 242 locations

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Phase 3

Recruiting

Conditions: Prostatic Neoplasms
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: Abiraterone acetate
Drug: Opevesostat
Drug: Dexamethasone
Drug: Prednisone acetate
Drug: Fludrocortisone acetate
Drug: Enzalutamide
Drug: Hydrocortisone

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1500

Registration Number: NCT06136650

Locations: 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇸🇬
National University Hospital ( Site 1201), Singapore, Central Singapore, Singapore
🇹🇭
Chulalongkorn University ( Site 1355), Bangkok, Krung Thep Maha Nakhon, Thailand

and more 264 locations